Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
Sampson J, Vlahovic G, Desjardins A, Friedman H, Baehring J, Hafler D, Rollin L, Coric V, Perez S, Reardon D. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). Journal Of Clinical Oncology 2014, 32: tps2101-tps2101. DOI: 10.1200/jco.2014.32.15_suppl.tps2101.Peer-Reviewed Original Research